199 related articles for article (PubMed ID: 19771431)
1. A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer.
Sunela KL; Koskinen S; Kellokumpu-Lehtinen PL
Cancer Chemother Pharmacol; 2010 May; 66(1):59-67. PubMed ID: 19771431
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity.
Segota E; Mekhail T; Olencki T; Hutson TE; Dreicer R; Wacker B; Osterwalder B; Elson P; Zhou M; Bukowski RM
Urol Oncol; 2007; 25(1):46-52. PubMed ID: 17208138
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: a phase II study.
Padrik P; Leppik K; Arak A
Urol Oncol; 2004; 22(5):387-92. PubMed ID: 15464918
[TBL] [Abstract][Full Text] [Related]
4. Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell cancer.
Amato RJ; Mohammad T
J Exp Ther Oncol; 2008; 7(1):41-7. PubMed ID: 18472641
[TBL] [Abstract][Full Text] [Related]
5. A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma.
Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Kanai F; Yokosuka AO
Invest New Drugs; 2014 Aug; 32(4):762-8. PubMed ID: 24737402
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma.
Pagliaro LC; Perez CA; Tu SM; Daliani DD
Urol Oncol; 2006; 24(6):487-91. PubMed ID: 17138128
[TBL] [Abstract][Full Text] [Related]
7. The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.
Harshman LC; Li M; Srinivas S
Am J Clin Oncol; 2008 Oct; 31(5):417-23. PubMed ID: 18838876
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.
Chan A; Conte PF; Petruzelka L; Tubiana-Mathieu N; Ganju V; Llombart A; Espie M; Majois F; Gil MG; Vaissiere N; Villanova G
Anticancer Res; 2013 Jun; 33(6):2657-64. PubMed ID: 23749924
[TBL] [Abstract][Full Text] [Related]
9. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer.
Négrier S; Caty A; Lesimple T; Douillard JY; Escudier B; Rossi JF; Viens P; Gomez F
J Clin Oncol; 2000 Dec; 18(24):4009-15. PubMed ID: 11118461
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.
Escudier B; Szczylik C; Hutson TE; Demkow T; Staehler M; Rolland F; Negrier S; Laferriere N; Scheuring UJ; Cella D; Shah S; Bukowski RM
J Clin Oncol; 2009 Mar; 27(8):1280-9. PubMed ID: 19171708
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma.
George S; Hutson TE; Mekhail T; Wood L; Finke J; Elson P; Dreicer R; Bukowski RM
Cancer Chemother Pharmacol; 2008 Jul; 62(2):347-54. PubMed ID: 17909807
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
[TBL] [Abstract][Full Text] [Related]
13. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951).
Aass N; De Mulder PH; Mickisch GH; Mulders P; van Oosterom AT; van Poppel H; Fossa SD; de Prijck L; Sylvester RJ
J Clin Oncol; 2005 Jun; 23(18):4172-8. PubMed ID: 15961764
[TBL] [Abstract][Full Text] [Related]
15. A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma.
Amato RJ; Khan M
Cancer Chemother Pharmacol; 2008 May; 61(6):1069-73. PubMed ID: 17701037
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
Gollob JA; Rathmell WK; Richmond TM; Marino CB; Miller EK; Grigson G; Watkins C; Gu L; Peterson BL; Wright JJ
J Clin Oncol; 2007 Aug; 25(22):3288-95. PubMed ID: 17664476
[TBL] [Abstract][Full Text] [Related]
17. Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study.
Allen MJ; Vaughan M; Webb A; Johnston S; Savage P; Eisen T; Bate S; Moore J; Ahern R; Gore ME
Br J Cancer; 2000 Oct; 83(8):980-5. PubMed ID: 10993642
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of cancer biotherapy research group 94-10.
Soori G; Dillman RO; Wiemann MC; Stark JJ; Tai F; DePriest CB; Church CK; Schulof R
Cancer Biother Radiopharm; 2002 Apr; 17(2):165-73. PubMed ID: 12030110
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy.
Petrioli R; Paolelli L; Francini E; Marsili S; Pascucci A; Sciandivasci A; de Rubertis G; Barbanti G; Manganelli A; Salvestrini F; Francini G
Anticancer Drugs; 2007 Aug; 18(7):817-20. PubMed ID: 17581304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
